The drug of abuse testing market is estimated to capture a valuation of US$ 1.65 billion in 2023 and is projected to reach US$ 2.69 billion by 2033. The market is estimated to secure a CAGR of 5.3% during the forecast period.
The sales of drug abuse testing kits are rising due to the high demand for rapid and accurate drug testing equipment in forensic laboratories, hospitals, and senior citizen care centers.
| Attribute | Details |
|---|---|
| Market CAGR (2023 to 2033) | 5.3% |
| Market Valuation (2023) | US$ 1.65 billion |
| Market Valuation (2033) | US$ 2.69 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Substance use disorders (SUDs) have emerged as a burden on society. In many parts of the world, annual surveys of drug and substance use in households, schools, and workplaces serve as one of the primary sources of information that indicate illicit drug use.
Increasing prescription drug abuse rates underpin the importance of adequate testing and abuse detection. Research also has shown substantial comorbidity of SUDs with psychiatric disorders and physical health issues.
However, drug abuse mapping has its challenges, which hinder research prospects in substance abuse epidemiology from devising modern solutions for drug abuse epidemics. Further, it is imperative to pinpoint factors that link with individual vulnerabilities of SUDs, such as genetics and social and environmental risk factors.
As deaths associated with fentanyl and other psychostimulants continue to rise and new psychoactive continue to emerge, methods of drug administration are also evolving. There has been a substantial rise in vaping of cannabis among teenagers and adolescents. Further, the COVID-19 outbreak has triggered drug overdoses and changes in drug use behaviors among homebound individuals.
The National Drug Early Warning System has launched a new system incorporating real-time surveillance to detect early signs of potential drug abuse. It includes 18 sentinel sites that utilize modern surveillance methods and gather data rapidly, securely, and timely.
Data collection in real-time is estimated to provide a comprehensive characterization of drug use and the availability of on-ground epidemiologic investigations in high-priority areas of concern. Such developments and the implementation of novel drug abuse testing guidelines are expected to propel sales of drug abuse testing over the assessment period.
Chronic pain is more common and complicated in the geriatric population. According to the National Institute of Health (NIH), up to 80% of patients with cancer and 77% with heart disease have reported persistent pain. Patients have been prescribed opioid medications for pain management-however, regular opioid usage results in addiction and compel patients to resort to cheaper drugs.
Besides this, the rising adoption of recreational marijuana for chronic pain management also fuels addiction problems. Ongoing research and medical trials indicate that medical marijuana can improve sleep hygiene, malnutrition, depression, and other side effects of cancer treatment.
Regular usage of marijuana for medical or recreational purposes leads to depression, impaired memory, adverse cardiovascular functions, altered judgment, and motor skills in the geriatric population. Cannabinoids can also interact with other prescription drugs and complicate pre-existing health issues in older adults.
As opioid dependence continues to rise, healthcare professionals and other medical institutes are running regular tests and screening of the elderly to diagnose signs of drug abuse early. It is expected to spur demand for drug abuse testing tools and equipment in hospitals and diagnostics.
Principal Consultant
As per Future Market Insights (FMI), the global market grew at a steady CAGR of 5.4% between 2018 and 2022. The market captured a valuation of US$ 1.2 billion in 2018 and US$ 1.5 billion in 2022.
Rising awareness regarding the high consumption of illicit drugs and overdose of prescribed medications is estimated to continue propelling demand for drug abuse testing systems. Additionally, increasing preference for on-the-spot and disposable testing methods for rapid drug abuse detection is expected to provide tailwinds to sales of drug abuse testing tools.
To gain a competitive edge, leading players operating in the global drug abuse testing market provide training on identifying and handling illicit drugs to law enforcement authorities through online services. Such initiatives are expected to create lucrative opportunities for drug abuse testing players over the forecast period.
As per National Centre for Drug Abuse Statistics, around 16.9% of American adults currently use marijuana. Marijuana is widely accepted as a recreational drug and is considered ‘less risky’ than other substances such as alcohol, tobacco, and painkillers.
The growing popularity of cannabinoids can be attributed to their acceptance in modern society. As it is considered less harmful, there has been less incidence of marijuana overdose. However, in some countries, the consumption of marijuana is illegal, even for recreational purposes. Marijuana addiction is rare, although overuse can still result in dementia, cardiovascular issues, and breathing disorders.
Owing to these factors, FMI has projected sales of drugs for abuse testing for cannabinoids to continue gaining momentum through 2033.
Demand for immunoassays is expected to rise steadily over the forecast period owing to a rising preference towards on-the-spot testing and higher adoption of disposable blood testing devices.
This technique is commonly used for drug testing in urine. Immunoassays are generally used for initial screening. Standard formats of immunoassays used for drugs of abuse comprise EMIT (enzyme multiplied immunoassay technique), CEDIA (cloned enzyme donor immunoassays technique), and KIMS (kinetic interaction of microparticle in solution).
Forensic drug chemistry is applied to identify illegal substances in the criminal justice system. Chemists use characteristics such as the interaction of atoms and molecules and chemical signatures, unique to only those substances.
Forensic chemistry covers aspects including drugs, explosives, and poisons. As per FMI, forensic laboratories are projected to remain the prominent drug abuse testing end-users. Growing demand for accurate and proper testing of individuals consuming illicit drugs and retailing illegal substances is expected to propel sales of drug abuse testing in forensic laboratories over the assessment period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Current Market Share |
|---|---|
| United States | 25.5% |
| Germany | 4% |
| Japan | 3.3% |
| Countries | Current Market CAGR |
|---|---|
| Australia | 6.2% |
| China | 6% |
| India | 6.7% |
| United Kingdom | 5.3% |
The rising prevalence of opioid dependence in the United States is expected to continue boosting demand for drug abuse testing tools and equipment. Substance abuse rates during the COVID-19 pandemic have grown substantially in the country, with more individuals dependent on cannabinoids for stress and anxiety relief. The United States is dominating the global market by registering a maximum share of 25.5% by 2033.
As per the National Centre for Drug Abuse Statistics, 53 million individuals over 12 have used illegal or misused prescription drugs in 2020. Commonly abused prescribed stimulants include Adderall, Modafinil, Ritalin, and Concerta. Non-sanctioned use of these drugs leads to drug abuse.
In response to the growing drug dependence among individuals in the United States, manufacturers are launching effective and accurate drug abuse testing kits. Along with novel product launches, key manufacturers are collaborating with research institutes and local authorities to spread awareness regarding drug abuse. It is expected to propel sales of drug abuse testing in the United States over the forecast period.
The Centre for Social Justice determined that snowballing drug addiction in the United Kingdom has made it the 'addiction capital of Europe.' Increasing usage of legal substances, mainly alcohol, and the usage of Class A drugs comprising heroin, meth, cocaine, and other hallucinogens are compelling authorities to launch drug testing protocols.
Causalities due to substance abuse in the United Kingdom affect users, their communities, and society. Due to the increasing costs of lab-based screening tests, hospitals, and drug management authorities are adopting on-the-spot testing kits. Manufacturers are developing easy-to-use and disposable drug-of-abuse testing systems to cater to high demand from hospitals and forensic labs.
The factors above are anticipated to offer lucrative opportunities for drug abuse testing market players operating in Europe, placing the United Kingdom as an attractive pocket for sales in the forthcoming years. The United Kingdom is securing a CAGR of 5.3% in the global market by 2033.
Consistent usage of illicit drugs can lead to adverse mental and physical health disorders, including cardiovascular diseases, fatal overdose, intentional or unintentional injuries, and even crime. China is registering a CAGR of 6% in the global market during the forecast period.
These issues later progress into clinical and social severity, difficulty managing daily activities, morbidity, and non-adherence to treatment. It, coupled with the growing prevalence of alcohol dependence in China, is compelling authorities to increase drug abuse testing among citizens.
Sales of drug abuse testing systems in China are expected to grow steadily. The presence of key manufacturers, along with the rapid expansion of the healthcare sector and easy availability of raw materials, are some factors expected to augment the market's growth through 2033.
The top 5 players operating in the global market comprise Quest Diagnostics, Roche Holding AG, Siemens AG (Siemens Healthineers), and Thermo Fisher Scientific, Inc., the top players accounting for maximum sales in the market.
Leading players operating in the global drug of abuse testing market are focusing on research and development to launch novel testing tools that are more effective and accurate. Players also invest in mergers, acquisitions, collaborations, and partnerships to expand their global footprint.
Other Essential Players in the Global Market are:
Recent Developments in the Global Market are:
Abbott Laboratories partnered with Intoximeters in August 2019, allowing the latter to market Abbott's SoToxaTM Mobile Test System. This is a handheld solution for oral fluid roadside testing. It has been designed to enable rapid detection of recent drug use.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | The United States, The United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Drug Type, Technique, End User, Region |
| Key Companies Profiled | Quest Diagnostics; Roche Holding AG; Thermo Fisher Scientific, Inc.; Siemens AG (Siemens Healthineers); Abbott Laboratories (Alere, Inc.); Shimadzu Corporation; Express Diagnostics International Inc.; Drägerwerk AG & Co. KGaA; Laboratory Corporation of America Holdings. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
In the current year 2023, the overall market size could be around US$ 1.65 billion.
Until 2033, the overall demand for drug of abuse testing services could progress at 5.3% CAGR.
The United States market players contributed for about 25.5% of the global market revenue in 2022.
Adoption of drug of abuse testing services in Germany held almost 4% market share in 2022.
The immunoassays testing type segment remains in higher demand for on-spot detection.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Psychostimulants 5.3.2. Narcotic 5.3.3. Cannabinoids 5.3.4. Sedatives 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technique 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Technique, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technique, 2023 to 2033 6.3.1. Immunoassay 6.3.2. Chromatography 6.3.3. Rapid Testing 6.4. Y-o-Y Growth Trend Analysis By Technique, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Technique, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis by End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast by End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Diagnostics Laboratories 7.3.3. Forensic Laboratories 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis by End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis by End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Technique 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Technique 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Technique 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Technique 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Technique 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Technique 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Type 12.2.3. By Technique 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Technique 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Technique 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Technique 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Type 14.2.3. By Technique 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Technique 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Technique 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Technique 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Technique 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Technique 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Technique 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Technique 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Technique 16.5.2.3. By End User 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Technique 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Technique 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Technique 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Technique 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Technique 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Technique 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Technique 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Technique 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Technique 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Technique 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Technique 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Technique 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Technique 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Technique 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Technique 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Technique 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Technique 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Quest Diagnostics 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Roche Holding AG 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Thermo Fisher Scientific, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Siemens AG (Siemens Healthineers) 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Abbott Laboratories (Alere, Inc.) 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Shimadzu Corporation 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Express Diagnostics International Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Drägerwerk AG & Co. KGaA 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Laboratory Corporation of America Holdings. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Bio-Rad Laboratories, Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Drug of Abuse Testing Market
